BR0014155A - Prevenção da miocardite, do aborto e da infecção intrauterina, associados com o circovìrus-2 porcino - Google Patents

Prevenção da miocardite, do aborto e da infecção intrauterina, associados com o circovìrus-2 porcino

Info

Publication number
BR0014155A
BR0014155A BR0014155-0A BR0014155A BR0014155A BR 0014155 A BR0014155 A BR 0014155A BR 0014155 A BR0014155 A BR 0014155A BR 0014155 A BR0014155 A BR 0014155A
Authority
BR
Brazil
Prior art keywords
abortion
myocarditis
prevention
porcine circovirus
infection
Prior art date
Application number
BR0014155-0A
Other languages
English (en)
Inventor
John Albert Ellis
Gordon Moore Allan
Brian Meehan
Edward Clark
Deborah Haines
Lori Hassard
John Harding
Catherine Elisabeth Charreyre
Gilles Emile Chappuis
George Steve Krakowka
Jean-Christophe Franc Audonnet
Francis Mcneilly
Original Assignee
Merial Sas
Univ Saskatchewan
Univ Belfast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26848763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0014155(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Sas, Univ Saskatchewan, Univ Belfast filed Critical Merial Sas
Publication of BR0014155A publication Critical patent/BR0014155A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patente de Invenção: "PREVENçãO DA MIOCARDITE, DO ABORTO E DA INFECçãO INTRA-UTERINA, ASSOCIADOS COM O CIRCOVìRUS-2 PORCINO". Acha-se descrito um poxvírus recombinante, tal como o avipoxvírus, contendo DNA estranho de circovírus (2) porcino. Acham-se descritas também composições imunológicas contendo o poxvírus recombinante para induzir uma resposta imunológica em um animal hospedeiro ao qual a composição imunológica seja administrada. São descritos também métodos de tratar ou prevenir doença causada pelo circovírus (2) porcino, mediante administração das composições imunológicas da invenção a um animal em necessidade do tratamento ou suscetível à infecção pelo circovírus (2) porcino.
BR0014155-0A 1999-08-31 2000-08-28 Prevenção da miocardite, do aborto e da infecção intrauterina, associados com o circovìrus-2 porcino BR0014155A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15156499P 1999-08-31 1999-08-31
US09/583,350 US6517843B1 (en) 1999-08-31 2000-05-31 Reduction of porcine circovirus-2 viral load with inactivated PCV-2
PCT/EP2000/008781 WO2001016330A2 (en) 1999-08-31 2000-08-28 Prevention of affections associated with porcine circovirus-2

Publications (1)

Publication Number Publication Date
BR0014155A true BR0014155A (pt) 2002-05-07

Family

ID=26848763

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0014155-0A BR0014155A (pt) 1999-08-31 2000-08-28 Prevenção da miocardite, do aborto e da infecção intrauterina, associados com o circovìrus-2 porcino
BRPI0014155-0A BRPI0014155B1 (pt) 1999-08-31 2000-08-28 Prevention of myocardial, abortion and intra-uterine infection, associated with porcine circovirus-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0014155-0A BRPI0014155B1 (pt) 1999-08-31 2000-08-28 Prevention of myocardial, abortion and intra-uterine infection, associated with porcine circovirus-2

Country Status (16)

Country Link
US (1) US6517843B1 (pt)
EP (1) EP1246920B1 (pt)
JP (1) JP2003513617A (pt)
KR (1) KR20020068325A (pt)
CN (2) CN102416173B (pt)
AT (1) ATE527361T1 (pt)
AU (2) AU782418B2 (pt)
BR (2) BR0014155A (pt)
CA (1) CA2383367C (pt)
DK (1) DK1246920T3 (pt)
ES (1) ES2376817T3 (pt)
HU (1) HU229195B1 (pt)
MX (1) MXPA02002208A (pt)
PL (1) PL205130B1 (pt)
PT (1) PT1246920E (pt)
WO (1) WO2001016330A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39494E1 (en) * 1992-02-27 2007-02-27 Intervet Inc. Inactivated mycoplasma hyopneumoniae and uses therefor
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
WO2001014047A1 (en) * 1999-08-20 2001-03-01 Asahi Kasei Kabushiki Kaisha Filter membranes for physiologically active substances
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY146518A (en) 2001-03-27 2012-08-15 Univ Saskatchewan Methods to culture circovirus.
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
MXPA06005424A (es) 2003-11-13 2007-01-25 Univ Georgia Res Found Metodos para caracterizar virus de enfermedad bursal infecciosa.
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
RU2620968C9 (ru) 2004-12-30 2017-08-08 Берингер Ингельгейм Ветмедика, Инк. Иммуногенные композиции pcv2 и способы получения таких композиций
US7566562B2 (en) 2005-02-03 2009-07-28 Universiteit Gent Culturing circular ssDNA viruses for the production of vaccines
US7300785B2 (en) 2005-02-03 2007-11-27 Universiteit Ghent Culturing circular ssDNA viruses for the production of vaccines
CN101277717A (zh) * 2005-09-09 2008-10-01 英特威国际有限公司 Pcv-2疫苗
DK2275132T3 (da) * 2005-12-29 2021-05-17 Boehringer Ingelheim Animal Health Usa Inc Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille dem
CA2635430A1 (en) * 2005-12-29 2007-08-23 Boehringer Ingelheim Vetmedica, Inc. Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
WO2008073464A2 (en) * 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
PT2094872T (pt) * 2006-12-15 2017-04-27 Boehringer Ingelheim Vetmedica Inc Tratamento de porcos seropositivos para o anticorpo anti-pcv2 com antigénio de pcv2
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CN101932336B (zh) * 2007-12-31 2014-07-09 贝林格尔.英格海姆维特梅迪卡有限公司 有外来氨基酸插入的pcv2 orf2病毒样颗粒
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
EP2254595A4 (en) * 2008-02-15 2012-12-05 Boehringer Ingelheim Vetmed METHODS AND COMPOSITIONS FOR REDUCING THE IMPACT OF ENTERIC DISEASES
KR20100135903A (ko) * 2008-04-16 2010-12-27 버지니아 테크 인터렉추얼 프라퍼티스, 인크. 키메라 돼지 써코바이러스 ＰＣＶ２Ｇｅｎ―１Ｒｅｐ 및 이의 용도
TWI627281B (zh) * 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
KR20110090711A (ko) * 2010-02-04 2011-08-10 녹십자수의약품(주) 신규한 돼지 써코바이러스 타입 2 및 그의 용도
KR101484469B1 (ko) * 2010-10-26 2015-01-21 주식회사 중앙백신연구소 돼지 써코바이러스 관련 질환을 예방하기 위한 ｐｃｖ-2의 전체 바이러스를 포함하는 혼합백신
TWI508974B (zh) 2010-12-22 2015-11-21 Sbc Virbac Ltd 豬第二型環狀病毒(Porcine Circovirus Type 2)、含彼之免疫組合物、檢測套組及其應用
CA2925281C (en) 2013-09-25 2022-05-03 Zoetis Services Llc Pcv2b divergent vaccine composition and methods of use
ES2778425T3 (es) 2013-10-02 2020-08-10 Boehringer Ingelheim Animal Health Usa Inc Variante de la proteína ORF2 del PCV2 y partículas similares a virus compuestas por esta
HK1252427A1 (zh) 2015-05-14 2019-05-24 Boehringer Ingelheim Animal Health USA Inc. 猪环状病毒生产方法和pcv2疫苗
US20230241198A1 (en) 2020-07-24 2023-08-03 Boehringer Ingelheim Animal Health USA Inc. Combination porcine vaccine
CN112655566B (zh) * 2020-12-18 2022-07-29 杭州惠通检测有限公司 一种在非洲猪瘟防控中应用的多层防御体系

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1990001543A1 (fr) 1988-07-29 1990-02-22 Intracel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
JPH04183026A (ja) 1990-11-16 1992-06-30 Matsushita Electric Ind Co Ltd 表示付き選択呼出受信装置
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US5869312A (en) 1992-01-13 1999-02-09 Syntro Corporation Recombinant swinepox virus
US6033904A (en) 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
EP0620277A1 (en) 1993-03-18 1994-10-19 Merck & Co. Inc. Nucleic acid pharmaceuticals
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
ATE475668T1 (de) 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
ES2243937T3 (es) 1994-04-29 2005-12-01 Baxter Healthcare S.A. Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños.
AU711702B2 (en) 1995-03-23 1999-10-21 Cambridge University Technical Services Limited Vectors for gene delivery
AU737243B2 (en) 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
JP3795751B2 (ja) 1997-12-11 2006-07-12 ユニバーシティ オブ サスカッチェワン ブタからの離乳後多全身系消耗症候群ウイルス
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US8235898B2 (en) 2004-08-27 2012-08-07 University Of Washington Through Its Center For Commercialization Ultrasonic direct strain estimation using temporal and spatial correlation

Also Published As

Publication number Publication date
ATE527361T1 (de) 2011-10-15
PL205130B1 (pl) 2010-03-31
KR20020068325A (ko) 2002-08-27
MXPA02002208A (es) 2002-11-07
CA2383367C (en) 2015-04-07
CN1409765A (zh) 2003-04-09
EP1246920B1 (en) 2011-10-05
BRPI0014155B1 (pt) 2017-09-12
WO2001016330A2 (en) 2001-03-08
DK1246920T3 (da) 2011-10-31
US6517843B1 (en) 2003-02-11
EP1246920A2 (en) 2002-10-09
CN102416173A (zh) 2012-04-18
PL353068A1 (en) 2003-10-06
AU7285500A (en) 2001-03-26
CN102416173B (zh) 2016-08-03
CA2383367A1 (en) 2001-03-08
AU2005220241A1 (en) 2005-12-01
JP2003513617A (ja) 2003-04-15
AU2005220241B2 (en) 2009-12-10
WO2001016330A3 (en) 2002-08-08
PT1246920E (pt) 2011-10-24
AU782418B2 (en) 2005-07-28
HU229195B1 (en) 2013-09-30
HUP0203834A2 (hu) 2003-03-28
ES2376817T3 (es) 2012-03-20
HUP0203834A3 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
BR0011737A (pt) Vacina de poxvìrus recombinante de circovìrus de porcino
WO2001016330A3 (en) Prevention of affections associated with porcine circovirus-2
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
BR0111956A (pt) Tratamento do vìrus do papiloma humano
DE69738351D1 (de) Verfaheren zur durch rekombinante adeno-assoziierte virus-gerichtete gentherapie
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
BR9814473A (pt) Imunógenos anti-retrovirais, preparação e uso
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
BR0210804A (pt) Vacinação de dose única com mycoplásma hyopneumoniae
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
EP1005376A4 (en) METHODS AND COMPOSITIONS FOR USE IN GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA
WO2001096587A8 (en) Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
BR0316244A (pt) Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo
BR9807112A (pt) Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato
BRPI0511776A (pt) vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR0206995A (pt) Tratamento do vìrus da hepatite b
FR2870126A1 (fr) Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
BR9807473A (pt) Tratamentos de doença relacionados à citocina
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
KR960013383A (ko) 항혈전성 및 피브린용해성 치료제와 조합하여 사용되는 치료제로서의 폰 빌레브란트 인자(vWF)-함유 농축물의 용도
BR0009644A (pt) Tratamento de carcinoma de célula renal
BR0014246A (pt) Utilização de uma proteìna ompa de enterobactéria, ou um de seus fragmentos, associada a um peptìdeo imunogênico derivado do vìrus respiratório sincicial
BR112023009276A2 (pt) Vírus recombinantes adenoassociados (raav), composição e uso do raav

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: O DEPOSITANTE DEVERA ULTILIZAR A PETICAO CONTIDA NO ANEXO II DA RESOLUCAO INPI NO 207/09 ( DECLARACAO NEGATIVA DE ACESSO ) FACE AO ACIMA EXPOSTO, O DEPOSITANTE DEVERA APRESENTAR A PETICAO DEVIDA PARA O CUMPRIMENTO DESTA EXIGENCIA EM ATE 60 ( SESSENTA ) DIAS, CONTADOS A PARTIR DA DATA DE PUBLICACAO NA RPI DE ACORDO COM O ART. 34 ( II ) DA LPI PARA QUE SE DE INICIO AO EXAME TECNICO DO PEDIDO.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 10 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.